anti-PD-1 antibody

Phase 2Biologic

Boehringer Ingelheim

anti-PD-1 antibody is one of 125 biologic programs targeting Chronic Hepatitis b. It is currently in Phase 2.

Indications

Total Trials

Active Trials

124

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Hepatitis BRecruiting

Malignant TumorsRecruiting

Advanced/metastatic Solid TumorsActive, not recruiting

Patients With Advanced Solid TumorsRecruiting

Relapsed or RefractoryRecruiting

Chronic Hepatitis BPhase 2

Recruiting

Malignant TumorsPhase 1

Recruiting

Advanced/metastatic Solid TumorsPhase 1

Active, not recruiting

Patients With Advanced Solid TumorsPhase 2

Recruiting

Relapsed or RefractoryPhase 2

Recruiting

Competition

Competitive Landscape

249 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

20 2

Eloxatin

Teva

Phase 2

9 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

23 4

Tecentriq

Roche

Phase 2

4 5

Camptosar

Pfizer

Phase 2

4 6

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

15 7

Trodelvy

Gilead

Phase 2

2 8

Erbitux

IImclone

Phase 2

10 9

Tuoyi

CCoherus Oncology, Inc.

Phase 2

9 10

Lazcluze

Johnson & Johnson

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Advanced/metastatic Solid Tumors

NCT05631899

Phase 1Recruiting

Malignant Tumors

NCT05631886

Phase 2Recruiting

Chronic Hepatitis B

NCT05769816

Phase 2Recruiting

Chronic Hepatitis B

NCT05771402

Q3 2027

Phase 1/2Recruiting

Patients With Advanced Solid Tumors

NCT05204862

Q4 2030

Phase 3Recruiting

Ovarian Cancer

NCT07822646

Clinical

Trials by Indication[1]

Pancreatic Cancer3 trials

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer

Unknown status·—·Phase 1/2·NCT03989310·50 enrolled

SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients

Terminated·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT03716596·8 enrolled

Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer

Unknown status·SShixiu Wu·Phase 2·NCT03374293·21 enrolled

Immunotherapy2 trials

A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC

Unknown status·—·Phase 1/2·NCT04004234·20 enrolled

Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases

Completed·—·Phase 1/2·NCT03757858·40 enrolled

Chronic Hepatitis b2 trials

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)

Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 2·NCT05769816·120 enrolled

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)

Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 2·NCT05771402·120 enrolled

Malignant Mesothelioma1 trial

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

Terminated·—·Phase 1/2·NCT03393858·10 enrolled

Advanced/Metastatic Solid Tumors1 trial

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

Active, not recruiting·—·Phase 1·NCT05631899·9 enrolled

10 more indications

Phase 11 trial

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

Completed·IIntensity Therapeutics, Inc.·Phase 1/2·NCT03058289·111 enrolled

Patients With Advanced Solid Tumors1 trial

Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

Recruiting·TTiumBio Co., Ltd.·Phase 1/2·NCT05204862·240 enrolled

Relapsed or Refractory1 trial

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Recruiting·HHan weidong·Phase 1/2·NCT02961101·250 enrolled

Lymphoma1 trial

A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas

Unknown status·—·Phase 1·NCT03991559·20 enrolled

Malignant Tumors1 trial

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Recruiting·—·Phase 1·NCT05631886·10 enrolled

Advanced Malignant Tumors1 trial

Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors

Completed·NNanjing Leads Biolabs Co.,Ltd·Phase 1/2·NCT05223231·26 enrolled

Triple-Negative Breast Cancer1 trial

Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

Unknown status·—·Phase 2·NCT05402722·30 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma

Unknown status·—·Phase 2·NCT04098796·30 enrolled

Ovarian Cancer1 trial

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Manganese-primed Immunochemotherapy in Subjects With Advanced Ovarian Cancer

Recruiting·CChinese PLA General Hospital·Phase 3·NCT07822646·120 enrolled

Solid Tumor1 trial

Phase I Open-label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination With an Anti-PD-1 mAb in Patients With Advanced or Metastatic Solid Tumors

Suspended· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05155332·190 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for anti-PD-1 antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — anti-PD-1 antibody compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for anti-PD-1 antibody. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Boehringer Ingelheim

anti-PD-1 antibody

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2030

Trials by Indication[1]

Pancreatic Cancer3 trials

Immunotherapy2 trials

Chronic Hepatitis b2 trials

Malignant Mesothelioma1 trial

Advanced/Metastatic Solid Tumors1 trial

Phase 11 trial

Patients With Advanced Solid Tumors1 trial

Relapsed or Refractory1 trial

Lymphoma1 trial

Malignant Tumors1 trial

Advanced Malignant Tumors1 trial

Triple-Negative Breast Cancer1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Ovarian Cancer1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News